Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\24378931.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Curr+Opin+Rheumatol 2014 ; 26 (2): 219-27 Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Prospects for Therapeutic Tolerance in Humans #MMPMID24378931
Baker KF; Isaacs JD
Curr Opin Rheumatol 2014[Mar]; 26 (2): 219-27 PMID24378931show ga
Purpose of review: To provide an overview of recent advances and future possibilities for therapeutic tolerance. Recent findings: Allograft survival despite complete immunosuppressant withdrawal has been demonstrated in selected renal transplant recipients with haematopoietic chimerism. Early clinical trials of mesenchymal stromal cell therapy have shown promising results in several autoimmune diseases. Regulatory T-cells show potential benefit in graft versus host disease, although challenges to ex vivo expansion remain. Targeted modulation of T-cell function in vivo with monoclonal antibodies have shown beneficial effects in phase II/III trials of multiple sclerosis (alemtuzumab) and type I diabetes mellitus (teplizumab, otelixizumab). Emerging data from animal models suggests an important role for the commensal microbiome in the maintenance and disruption of immune tolerance with parallels in human studies. Summary: After years of slow progress, recent research has reduced the translational gap between animal models and clinical therapeutic tolerance. Early detection of autoimmunity, potentially at preclinical stages, offers a window of opportunity for tolerogenic therapy. Reliable biomarkers of tolerance are urgently needed to provide objective measurements of the effectiveness of tolerogenic therapies, and to allow for intelligent immunosuppressant withdrawal in patients whose autoimmune disease is stable.Video Abstract
free
free
free
Curr+Opin+Rheumatol 2014 ; 26 (2): 219-27
